Evolent Health (EVH) Common Equity (2014 - 2026)

Evolent Health has reported Common Equity for 13 years, with the latest figure at $383.2 million in Q2 2026.

• On a quarterly basis, Common Equity fell 57.23% year-over-year to $383.2 million in Q2 2026; TTM through Jun 2026 was $383.2 million, a 57.23% decrease from a year earlier, with the FY2025 full-year figure at $415.2 million, down 58.53% from the prior year.
• Common Equity was $383.2 million for Q2 2026 at Evolent Health, down from $396.4 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2023, with the low at $383.2 million in Q2 2026.
• Average Common Equity over 5 years is $851.6 million, with a median of $915.8 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Common Equity surged 83.53% in 2023, then slumped 58.53% in 2025.
• Over 5 years, Common Equity stood at $859.4 million in 2022, then rose by 24.24% to $1.1 billion in 2023, then retreated by 6.22% to $1.0 billion in 2024, then plunged by 58.53% to $415.2 million in 2025, then slipped by 7.7% to $383.2 million in 2026.
• The last three Common Equity figures came in at $383.2 million (Q2 2026), $396.4 million (Q1 2026), and $415.2 million (Q4 2025), per Business Quant data.